假手术对照随机试验中经导管肾去交感神经术对高血压患者的疗效
该研究纳入6项假手术对照随机试验共977例高血压患者,采用随机效应荟萃分析评估经导管肾去交感神经术(RSD)的降压效果。结果显示RSD较假手术显著降低24小时动态收缩压(WMD -3.65 mmHg,95%CI -5.33至-1.98,p<0.001)及诊室收缩压等指标。结论提示RSD可显著降低血压,结果可为设计更大规模关键试验提供参考。
要点
- RSD较假手术显著降低24小时动态收缩压达3.65 mmHg。
- 诊室收缩压降幅更大(WMD -5.53 mmHg),舒张压亦显著下降。
- 第二代试验日间动态收缩压降幅大于第一代(6.12 vs 2.14 mmHg,交互p=0.04)。
核心结论
- 与假手术对照相比,经导管肾去交感神经术可显著降低高血压患者的血压。
- 该荟萃分析结果可为设计更大规模关键试验以评估RSD长期疗效和安全性提供参考。
研究设计与样本
- 检索截至2018年6月30日的数据库,纳入比较经导管RSD与假手术对照、样本量≥50例的随机对照试验。
- 共纳入6项试验、977例患者,采用随机效应荟萃分析计算加权均数差(WMD)及95%置信区间(CI)。
主要发现
- RSD组24小时动态收缩压(ASBP)降幅显著大于假手术组(WMD -3.65 mmHg,95%CI -5.33至-1.98,p<0.001)。
- 日间ASBP(WMD -4.07 mmHg,95%CI -6.46至-1.68,p<0.001)和诊室收缩压(WMD -5.53 mmHg,95%CI -8.18至-2.87,p<0.001)降幅亦显著更大。
- 24小时动态舒张压(WMD -1.71 mmHg,95%CI -3.06至-0.35,p=0.01)、日间动态舒张压(WMD -1.57 mmHg,95%CI -2.73至-0.42,p=0.008)和诊室舒张压(WMD -3.37 mmHg,95%CI -4.86至-1.88,p<0.001)均显著降低。
- 第二代试验日间ASBP降幅显著大于第一代(6.12 mmHg vs. 2.14 mmHg,交互p=0.04),但24小时ASBP的交互作用不显著(4.85 mmHg vs. 2.23 mmHg,交互p=0.13)。
临床怎么用
- 对于假手术对照试验所代表的高血压人群,RSD可作为一种显著降低动态和诊室血压的器械治疗选择。
- 第二代RSD试验显示日间动态收缩压降幅更大,临床选择器械或技术时可参考代际差异。
- 该证据支持在难治性高血压等合适人群中进一步开展长期疗效与安全性评估。
局限性
- 仅纳入6项试验、977例患者,样本量有限。
- 纳入试验均设有假手术对照,但未报告长期硬终点事件。
- 第一代与第二代试验间日间ASBP降幅差异显著,但24小时ASBP交互作用不显著,代际差异需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are conflicting data regarding the relative effectiveness of renal sympathetic denervation (RSD) in patients with hypertension. OBJECTIVES: The purpose of this study was to evaluate the blood pressure (BP) response after RSD in sham-controlled randomized trials. METHODS: Databases were searched through June 30, 2018. Randomized trials (RCTs) with ≥50 patients comparing catheter-based RSD with a sham control were included. The authors calculated summary treatment estimates as weighted mean differences (WMD) with 95% confidence intervals (CIs) using random-effects meta-analysis. RESULTS: The analysis included 977 patients from 6 trials. The reduction in 24-h ambulatory systolic blood pressure (ASBP) was significantly greater for patients treated with RSD than sham procedure (WMD -3.65 mm Hg, 95% CI: -5.33 to -1.98; p < 0.001). Compared with sham, RSD was also associated with a significant decrease in daytime ASBP (WMD -4.07 mm Hg, 95% CI: -6.46 to -1.68; p < 0.001), office systolic BP (WMD -5.53 mm Hg, 95% CI: -8.18 to -2.87; p < 0.001), 24-h ambulatory diastolic BP (WMD -1.71 mm Hg, 95% CI: -3.06 to -0.35; p = 0.01), daytime ambulatory diastolic BP (WMD -1.57 mm Hg, 95% CI: -2.73 to -0.42; p = 0.008), and office diastolic BP (WMD -3.37 mm Hg, 95% CI: -4.86 to -1.88; p < 0.001). Compared with first-generation trials, a significantly greater reduction in daytime ASBP was observed with RSD in second-generation trials (6.12 mm Hg vs. 2.14 mm Hg; p interaction = 0.04); however, this interaction was not significant for 24-h ASBP (4.85 mm Hg vs. 2.23 mm Hg; p interaction = 0.13). CONCLUSIONS: RSD significantly reduced blood pressure compared with sham control. Results of this meta-analysis should inform the design of larger, pivotal trials to evaluate the long-term efficacy and safety of RSD in patients with hypertension.
引用
- Sardar P, Bhatt DL, Kirtane AJ, et al. Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension. J Am Coll Cardiol. 2019. PMID: 30947915. doi:10.1016/j.jacc.2018.12.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。